Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibiltion

被引:148
作者
Lamprecht, A
Benoit, JP
机构
[1] Univ Franche Comte, Fac Med & Pharm, Lab Pharmaceut Engn, F-25030 Besancon, France
[2] Univ Angers, INSERM, U646, F-49100 Angers, France
关键词
nanoparticles; cancer; glioma; lipid nanocapsules; etoposide; P-glycoprotein; multidrug resistance;
D O I
10.1016/j.jconrel.2006.02.014
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
In cancer treatment, efficient therapeutic strategies could be impeded by cellular mechanisms such as the multidrug resistance. Recently, drugloaded nanoparticles have been reported to be useful, since they allow entering the cancer cell and act as an intracelluilar anti-cancer drug reservoir. A new approach is proposed here by the use of lipid nanocapsules (LNC) which were hypothesized to reverse multidrug resistance additionally by their P-glycoprotein (P-gp) inhibiting surfactant. LNC (mean diameter 25 to 100 nm) were loaded with etoposide, tested for the drug release and their efficiency to reduce cell growth in cell culture for C6, F98, and 9L glioma cell lines. Sustained etoposide release can be provided over a period of 1 week (t(10%): 1.4 +/- 0.1 h; t(50%): 15.9 +/- 2.8 h). The P-gp inhibiting activity in-vitro was found to be independent from the LNC size. In cell culture, an internalization of LNC was observed in all glioma cell types. Etoposide LNC showed a generally higher efficiency than the drug solution while blank LNC were found to be less inhibitory than the pure drug at equivalent concentrations (IC50: C6: etoposide: 25.2 mu M; LNC: 2.6-8.9 mu M, F98: etoposide: 46.5 mu M; LNC: 1.4-14.7 mu M, 9L: etoposide: 58.2 mu M; LNC: 4.4-12.7 mu M). This effect was found to be particle size dependent within a range of an 8- (C6) to 33-fold (1798) increased cytotoxicity for smallest particles. When cells were incubated with etoposide solution in the presence of blank LNC, a slight growth inhibition was observed, however, distinctly lower than the drug-trapping particles. Moreover, cell toxicity on astrocytes was similar for etoposide LNC and etoposide solution. The mechanism of action of etoposide LNC was proposed to be a cell uptake followed by a sustained drug release from the LNC in combination with an intracellular P-gp inhibition ensuring a higher anticancer drug concentration inside the cancer cells. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:208 / 213
页数:6
相关论文
共 32 条
[1]  
ABE T, 1994, INT J CANCER, V58, P860
[2]  
Batrakova EV, 2001, J PHARMACOL EXP THER, V299, P483
[3]   Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells [J].
Batrakova, EV ;
Li, S ;
Alakhov, VY ;
Miller, DW ;
Kabanov, AV .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 304 (02) :845-854
[4]   ENHANCED CYTOTOXICITY OF DOXORUBICIN ENCAPSULATED IN POLYISOHEXYLCYANOACRYLATE NANOSPHERES AGAINST MULTIDRUG-RESISTANT TUMOR-CELLS IN CULTURE [J].
BENNIS, S ;
CHAPEY, C ;
COUVREUR, P ;
ROBERT, J .
EUROPEAN JOURNAL OF CANCER, 1994, 30A (01) :89-93
[5]  
Buckingham LE, 1996, INT J CANCER, V65, P74
[6]   COMPARISON OF SOLUTOL HS-15, CREMOPHOR EL AND NOVEL ETHOXYLATED FATTY-ACID SURFACTANTS AS MULTIDRUG-RESISTANCE MODIFICATION AGENTS [J].
BUCKINGHAM, LE ;
BALASUBRAMANIAN, M ;
EMANUELE, RM ;
CLODFELTER, KE ;
COON, JS .
INTERNATIONAL JOURNAL OF CANCER, 1995, 62 (04) :436-442
[7]  
COON JS, 1991, CANCER RES, V51, P897
[8]  
Denecke J, 1997, ANTICANCER RES, V17, P4531
[9]   Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: Towards a mechanism of action [J].
deVerdiere, AC ;
Dubernet, C ;
Nemati, F ;
Soma, E ;
Appel, M ;
Ferte, J ;
Bernard, S ;
Puisieux, F ;
Couvreur, P .
BRITISH JOURNAL OF CANCER, 1997, 76 (02) :198-205
[10]  
DEVERDIERE AC, 1994, CANCER CHEMOTH PHARM, V33, P504